News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InNexus Biotechnology Inc. (IXS) Expands Team to Focus on Licensing and Partnering


3/16/2011 10:53:48 AM

CHANDLER, Ariz.--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX:IXS.V) (www.ixsbio.com), a leading drug development company commercializing the next generation of antibodies based on its proprietary DXL™ and Transmab™ technologies, today announced the appointment of Jonathan Drutz as Business Development Director. Drutz will lead all licensing, business development and partnering initiatives and programs for InNexus’ DXL™ and Transmab™ antibody technologies.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES